Common Stock, par value $0.0001 per share
- Symbol
- DRMA
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01 · 8-K
Dermata Therapeutics, Inc.
DRMANASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On October 29, 2027, Dermata Therapeutics, Inc. (the “Company”) issued a press release announcing enrollment of the first participant in a clinical trial evaluating Tome Clearing Treatment, the Company’s once-weekly acne treatment, in participants with acne. The Company expects to launch this second commercial product in the first half of 2027.
Company context
Dermata Therapeutics is a scientific leader in dermatologic solutions that recently announced a strategic pivot from pharmaceutical development to begin focusing on the development and commercialization of direct-to-consumer skincare solutions. The Company is currently developing a first-of-its-kind skin renewal treatment which incorporates Dermata’s Bioneedle™. The Company expects to launch its first product on August 25, 2026, with additional innovations planned to follow. Dermata is headquartered in San Diego, California. For more information, or to join our mailing list, please visit http://www.dermatarx.com/.
Current securities
Historical securities (1)
Registered securities in this filing
DERMATA THERAPEUTICS, INC. · 8-K · Filed 2026-10-29
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item
8.01. Other Events.
On
October 29, 2027, Dermata Therapeutics, Inc. (the “Company”) issued a press release announcing enrollment
of the first participant in a clinical trial evaluating Tome Clearing Treatment, the Company’s once-weekly acne treatment, in participants
with acne. The Company expects to launch this second commercial product in the first half of 2027.